Matches in Wikidata for { <http://www.wikidata.org/entity/Q66064486> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q66064486 description "clinical trial" @default.
- Q66064486 description "ensayu clínicu" @default.
- Q66064486 description "klinisch onderzoek" @default.
- Q66064486 description "клінічне випробування" @default.
- Q66064486 name "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 name "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 type Item @default.
- Q66064486 label "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 label "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 prefLabel "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 prefLabel "A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 P1132 Q66064486-AB1C0929-EFFA-4AC2-951B-17EEB672E2C7 @default.
- Q66064486 P1476 Q66064486-471A640B-17A4-4E65-824F-65C2BF8319DA @default.
- Q66064486 P17 Q66064486-6B5B7988-CE04-4D18-BE37-F656B0EFACD6 @default.
- Q66064486 P2899 Q66064486-08479B2E-CA36-4E2F-A7AD-42ADCAAE074E @default.
- Q66064486 P3098 Q66064486-EA19F536-31BF-43A9-A66E-5A2E41B1E506 @default.
- Q66064486 P31 Q66064486-7977727B-38F4-4642-A5C2-6C20E96385CA @default.
- Q66064486 P4135 Q66064486-77CA3C31-2EEA-4EAF-8767-242A933EFF97 @default.
- Q66064486 P4844 Q66064486-27F244C3-73A2-4385-8F16-E8655F2C0C8A @default.
- Q66064486 P580 Q66064486-223CF8BD-FD50-4F2C-9F75-9D55B7FCF373 @default.
- Q66064486 P582 Q66064486-9B58C938-2DE9-4FEE-A59C-D6251A2FFFBF @default.
- Q66064486 P6099 Q66064486-92923D74-79C6-46DB-990F-D74A820487C2 @default.
- Q66064486 P8363 Q66064486-750A4260-E2D8-4694-9D06-CF752825F72E @default.
- Q66064486 P1132 "+34" @default.
- Q66064486 P1476 "A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers" @default.
- Q66064486 P17 Q41 @default.
- Q66064486 P2899 "+18" @default.
- Q66064486 P3098 "NCT03975166" @default.
- Q66064486 P31 Q30612 @default.
- Q66064486 P4135 "+60" @default.
- Q66064486 P4844 Q27264747 @default.
- Q66064486 P580 "2019-05-21T00:00:00Z" @default.
- Q66064486 P582 "2019-06-25T00:00:00Z" @default.
- Q66064486 P6099 Q5452194 @default.
- Q66064486 P8363 Q78089383 @default.